Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01027650
Recruitment Status : Completed
First Posted : December 8, 2009
Results First Posted : April 29, 2014
Last Update Posted : April 29, 2014
Sponsor:
Information provided by (Responsible Party):
Allergan

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion. This study is being conducted in two stages: Stage 1 will enroll approximately 21 subjects who will receive a single open label intravitreal injection of either 75 ug, 300 ug, 600 ug or 900 ug of AGN208397 and be followed for 12 months post treatment; based on Stage 1 results, Stage 2 will enroll approximately 96 subjects who will receive a single masked intravitreal injection of one of three doses of AGN208397 or Ozurdex® and be followed for 12 months post treatment.

Condition or disease Intervention/treatment Phase
Macular Edema Retinal Vein Occlusion Drug: AGN208397 intravitreal injection Drug: dexamethasone intravitreal implant Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : March 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Stage 1 Cohort 1
AGN208397 intravitreal injection 75 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Experimental: Stage 1 Cohort 2
AGN208397 intravitreal injection 300 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Experimental: Stage 1 Cohort 3
AGN208397 intravitreal injection 600 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Experimental: Stage 1 Cohort 4
AGN208397 intravitreal injection 900 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Experimental: Stage 2 Arm 1
AGN208397 intravitreal injection 600 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Experimental: Stage 2 Arm 2
AGN208397 intravitreal injection 450 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Experimental: Stage 2 Arm 3
AGN208397 intravitreal injection 300 ug on Day 1.
 Drug: AGN208397 intravitreal injection
AGN208397 intravitreal injection on Day 1.
Active Comparator: Stage 2 Arm 4
Dexamethasone 700 ug intravitreal implant on Day 1.
 Drug: dexamethasone intravitreal implant
Dexamethasone 700 ug intravitreal implant on Day 1.
Other Name: Ozurdex®


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 1 [ Time Frame: Baseline, Month 1 ]
    Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.

  2. Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 2 [ Time Frame: Baseline, Month 1 ]
    Retinal thickness is assessed by OCT in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.

  3. Change From Baseline at Month 1 in Best Corrected Visual Acuity (BCVA) in the Study Eye During Stage 1 [ Time Frame: Baseline, Month 1 ]
    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

  4. Change From Baseline at Month 1 in BCVA in the Study Eye During Stage 2 [ Time Frame: Baseline, Month 1 ]
    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.


Secondary Outcome Measures :
  1. Change From Baseline at Month 12 in Retinal Thickness in the Study Eye During Stage 1 [ Time Frame: Baseline, Month 12 ]
    Retinal thickness is assessed by OCT in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.

  2. Change From Baseline at Month 12 in Retinal Thickness in the Study Eye During Stage 2 [ Time Frame: Baseline, Month 12 ]
    Retinal thickness is assessed by OCT in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.

  3. Change From Baseline at Month 12 in BCVA in the Study Eye During Stage 1 [ Time Frame: Baseline, Month 12 ]
    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

  4. Change From Baseline at Month 12 in BCVA in the Study Eye During Stage 2 [ Time Frame: Baseline, Month 12 ]
    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • macular edema due to retinal vein occlusion
  • visual acuity in the study eye between 20/320 to 20/40

Exclusion Criteria:

  • cataract surgery or Lasik within 3 months prior to study Day 1 or anticipated need for cataract surgery during study period (12 months)
  • use of injectable drugs in the study eye within 2 months prior to day 1
  • active eye infection in either eye
  • visual acuity in the non-study eye of 20/200 or worse
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01027650


Locations
Layout table for location information
United States, Arizona
Phoenix, Arizona, United States
Australia, Victoria
East Melbourne, Victoria, Australia
Canada, Ontario
London, Ontario, Canada
Israel
Tel Aviv, Israel
South Africa
Cape Town, South Africa
Sponsors and Collaborators
Allergan
Investigators
Layout table for investigator information
Study Director: Medical Director Allergan
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01027650    
Other Study ID Numbers: 208397-001
First Posted: December 8, 2009    Key Record Dates
Results First Posted: April 29, 2014
Last Update Posted: April 29, 2014
Last Verified: March 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Retinal Vein Occlusion
Edema
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
 Dexamethasone
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents